Question 1

What is ORPATHYS?

Accepted Answer

ORPATHYS is a Other.

Question 2

How often does ORPATHYS appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was ORPATHYS first tracked by Ergen?

Accepted Answer

First tracked on Jul 02, 2026.

Question 4

When was ORPATHYS last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is ORPATHYS's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ORPATHYS in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ORPATHYS?

Accepted Answer

ORPATHYS Approved for Gastric Cancer in China (Jul 02, 2026, 6 articles).

Question 8

How did the "ORPATHYS Approved for Gastric Cancer in China" event impact ORPATHYS?

Accepted Answer

ORPATHYS (savolitinib), a selective MET inhibitor, received conditional approval in China for treating MET-amplified advanced gastric cancer, expanding its market and therapeutic application.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.